BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
December 12, 2017 at 11:40 AM EST
* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA
